IMNN

Business Context and Reporting Period

This Form 10-Q covers Celsion Corporation (noted as Imunon, Inc. in metadata) for the quarterly and nine-month periods ended June 30, 2002. The company is a clinical-stage biotechnology firm focused on thermotherapy systems for treating cancer and benign prostatic hyperplasia (BPH). As of the reporting date, the company had no commercial product sales and was in the process of conducting pivotal Phase II clinical trials for its new equipment.

Key Financial Metrics

Liquidity: The company funded operations primarily through equity financing. Net cash used in operating activities for the nine months ended June 30, 2002, was $6,961,305. Financing activities provided $7,615,008, primarily from private placements of preferred stock and common stock.

Material Changes vs. Prior Period

• Revenue: Revenue remained at zero for the current period, consistent with the prior year, as no products have received regulatory approval for sale.
• Operating Expenses:
  • Three Months: Total operating expenses increased 57% to $2.63 million from $1.68 million. Research and Development (R&D) expenses surged 198% to $1.65 million due to BPH clinical trial costs and engineering expenses.
  • Nine Months: Total operating expenses increased 66% to $8.06 million from $4.84 million. R&D expenses rose 151% to $4.53 million. General and Administrative (G&A) expenses increased 16% to $3.53 million, driven by a legal settlement with the Stearns Group and accrued retirement payments to the former CEO.
• Net Loss: The net loss for the nine-month period increased by approximately 75% compared to the prior year, reflecting the significant ramp-up in clinical trial and administrative costs.

Guidance, Outlook, and Risks

Outlook: Management expects operating losses to continue and possibly increase in the near term. The company anticipates expending approximately $9.5 million for the full fiscal year 2002, with $7.1 million already expended as of June 30, 2002. No product revenues are expected until new technologies receive FDA approval.

Key Developments:

• Clinical Trials: The company is completing Phase II trials for its BPH device and intends to accelerate Phase II breast cancer trials. An Investigational New Drug (IND) application for prostate cancer treatment was submitted to the FDA.
• Capital Raising: The company completed two private placements in the fiscal year, raising $2.0 million in June 2002 (Series B Preferred Stock) and $6.25 million in January 2002 (Common Stock).
• Stock Option Repricing: In March 2002, the company cancelled and reissued options to key executives to align exercise prices with the current market value, resulting in a net decrease of 475,000 options.

Risks: The company has no committed sources of additional financing. If adequate funds are not available, the company may be forced to delay or scale back operations. Success depends on clinical trial results, regulatory approvals, and the ability to commercialize thermotherapy systems.

Investor Verification Checklist

• Cash Runway: Verify if the $3.1 million cash balance is sufficient to fund the remaining $2.4 million estimated expenditure for fiscal year 2002 without further dilution.
• Regulatory Milestones: Monitor the status of the FDA review for the BPH device and the acceptance of the IND application for prostate cancer liposomes.
• Dilution Risk: Review the terms of the Series B Convertible Preferred Stock (convertible into 2,000 shares of common stock per preferred share) and the associated warrants.
• Legal Settlements: Confirm the final cash and equity impact of the settlement with the Stearns Group and the former CEO's retirement package.
• Option Accounting: Assess the future compensation expense impact of the repriced stock options under FASB Interpretation No. 44.